Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
Steven W. Andrews, Boulder, CO (US); James F. Blake, Boulder, CO (US); Julia Haas, Boulder, CO (US); Yutong Jiang, Boulder, CO (US); Gabrielle R. Kolakowski, Boulder, CO (US); David A. Moreno, Boulder, CO (US); Li Ren, Boulder, CO (US); and Shane M. Walls, Boulder, CO (US)
Assigned to Array BioPharma Inc., Indianapolis, IN (US)
Filed by Array BioPharma Inc., Indianapolis, IN (US)
Filed on Oct. 29, 2021, as Appl. No. 17/514,684.
Application 17/514,684 is a continuation of application No. 16/478,071, granted, now 11,168,090, previously published as PCT/US2018/014279, filed on Jan. 18, 2018.
Claims priority of provisional application 62/447,862, filed on Jan. 18, 2017.
Prior Publication US 2022/0119396 A1, Apr. 21, 2022
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of claim 1, or a pharmaceutically acceptable salt thereof.